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Abstract
Determination of the exact criteria for resectability in patients with cholangiocarcinoma and how they are most efficiently
evaluated has many limitations. Among many factors taken into account in this decision-making process are: the condition
of the patient, the biology of the disease, and the technical expertise of the surgeon and hospital. An attempt is made here to
organize recommendations for the work-up of patients and the main criteria for resectability as best possible, keeping in
mind that there will always be some limited room for exceptions, especially if the biology is favorable. Work-up and
determination of resectability for patients with distal cholangiocarcinoma are more straightforward than at the other two
sites of the disease (perihilar and peripheral). In general, these follow the same principles as those for other periampullary
carcinomas (pancreas, ampullary, and duodenal). The work-up and determination of resectability for patients with
peripheral cholangiocacrcinoma can be relatively straightforward if the lesion is away from the hilus of the liver and does not
involve a significant proportion of parenchyma, but can be problematic if it is more central or very large. Patients with
perihilar cholangiocarcinomas are perhaps the most challenging, as factors such as patient condition, biology of the disease,
local involvement of the major vessels and bile ducts at the hilum, and the future liver remnant all have a bearing in the
decision-making process.
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Introduction
A unified algorithm for use when staging patients with
cholangiocarcinoma and when determining the exact
criteria of unresectability has many challenges. First,
the three major sites of cholangiocarcinoma (periph-
eral, hilar, and distal) have different characteristics
and unique issues in terms of staging and resectability.
Because of the relative rarity of the disease, there is a
paucity of randomized controlled clinical trials dealing
with issues of staging and resectability. Most publica-
tions dealing with staging and resectability of cholan-
giocarcinoma are either radiological papers on
technical aspects of the various modalities, or they
are retrospective reports of results of single institu-
tional series (some of which collect data in a pro-
spective database). Therefore, the preponderance of
evidence in this report is from observational studies;
using ‘‘GRADE quality assessment criteria’’ [1] would
be considered low quality evidence. Because of the
consistency of multiple reports agreeing, however,
some of the data may be considered of moderate
quality, but there is great potential bias in these
reports. Consensus statements are given at the end
of the article.
Peripheral cholangiocarcinoma
Peripheral cholangiocarcinoma, the least frequent
type, has been much more aggressively resected
over the past 1015 years at centers specializing in
hepatopancreatobiliary diseases. Lang et al. [2]
reported on a series of 50 patients who were explored
between 1998 and 2005. Twenty-seven patients
underwent extended right or left hepatectomy, in-
cluding resection of the hilar bifurcation in 12,
diaphragm in 6, portal vein in 5, vena cava in 4,
left hepatic vein and reconstruction in 1, and hepatic
artery and reconstruction in 1. This was accom-
plished with an overall operative mortality of 4% and
a margin negative resection rate of 59%. They also
nicely summarize the results of multiple other centers
that have taken the same approach with similar
results.
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Two methodologies that have evolved relatively
recently are the use of fluorodeoxyglucose positron
emission tomography (FDG-PET) and staging la-
paroscopy. Petrowsky et al. [3] reported on their
experience with PET scans in patients with biliary
cancers. In patients with cholangiocarcinoma, they
demonstrate high sensitivity (93%) for detecting the
primary lesion in peripheral cholangiocarcinoma, but
moderate sensitivity (55%) for detecting the primary
lesion in hilar cholangiocarcinoma. This modality was
very sensitive at detecting distant metastatic disease
(100%) but poor at detecting locoregional lymphade-
nopathy (12%). Goere et al. [4] reported on the use
of staging laparoscopy in 39 patients with biliary
cancers. Fourteen of 39 patients were found to be
unresectable, thus saving 38% of the patients from
potentially unnecessary laparotomy. However, when
the 25 remaining patients were taken to laparotomy, a
further 9 were found to be unresectable because
of vascular invasion (5), advanced nodal spread (3),
liver metastases (2), peritoneal metastases (1), and
adjacent organ infiltration (1). They concluded that
laparoscopy was sensitive at detecting peritoneal and
liver metastases, but not so good at detecting distant
lymph node involvement or vascular invasion.
Hilar cholangiocarcinoma
In the past 10 years, there have been increasing
reports of aggressive resections for hilar cholangio-
carcinoma. Nimura et al. [5] reported on their series
of 142 patients who underwent exploration for hilar
cholangiocarcinoma. Of these, 108 underwent cura-
tive resection and included 100 who underwent
hepatectomy, 43 portal vein resections, and 16
pancreatoduodenectomy with hepatectomy. The
5-year survival rate for those undergoing hepatectomy
was 26% and 16% for those who did not. Miyazaki
et al. [6] reported a similar experience in that patients
who underwent portal vein resection to achieve a
negative margin did better than those who had a
margin-positive resection without vein resection.
They stated that portal vein resection had acceptable
operative morbidity and could improve prognosis.
However, in summarizing the results of the nine
patients who underwent hepatic artery resection,
they reported that hepatic artery resection could not
be justified. Neuhaus et al. [7] reported on the benefit
of portal vein resection with extended right hepatect-
omy. Patients who underwent margin negative portal
vein resection with extended right hepatectomy had a
5-year survival rate of 72%, whereas those who did
not have portal vein resection but had a margin
negative resection with extended right hepatectomy
had a 5-year survival rate of 52%.
Conner et al. [8] reported on the role of staging
laparoscopy in patients with hilar cholangiocarci-
noma. Eighty-four patients underwent laparoscopy
for presumed hilar cholangiocarcinoma. Thirty-five
where found to be unresectable at laparoscopy and 19
at laparotomy; 20 were resectable. The overall yield of
laparoscopy was thus 42%, which is significantly
higher than in other reported studies. The authors
comment that this could have been because of
the extensive use of laparoscopic ultrasound during
laparoscopy.
Distal cholangiocarcinoma
Patients with distal cholangiocarcinoma are in general
more straightforward in terms of work-up and criteria
of resectability. De Oliveira et al. [9] reported on a
series of 239 patients explored with distal cholangio-
carcinoma. The resection rate was 96%, while the
margin-negative resection rate was 82%.
Conclusions
Cholangiocarcinoma comprises a broad spectrum of
disease with diverse options for resection depending
on location and involvement. Resection provides the
only hope of long-term survival. Margin-negative
resection is a strong prognostic factor. Resectability
at laparotomy remains challenging, but imaging
techniques are easing the selection process. Radical
resections, including extended hepatectomies for hilar
and peripheral tumors, are more common and more
often yield negative margins. Efficient but complete
staging of patients is paramount to correctly selecting
those most likely to benefit from these radical opera-
tions and to avoid unnecessary laparotomy in those
who will not.
Consensus statements
. For consideration of resectability for peripheral
cholangiocarcinoma (Figure 1), patients must
be medically fit for resection. They should be
subject to appropriate preoperative studies in-
cluding those focusing on hepatic function and
more direct studies in accordance with their
medical history. They should be studied for
presence of metastatic disease in the peritoneal
cavity and thorax and elsewhere if symptomatic.
Typically, a high definition CT scan of the chest,
abdomen and pelvis is sufficient. Lastly, local
involvement of the main tumor mass should be
studied with particular attention to vascular in-
flow, vascular outflow, hepatic parenchyma, and
the biliary tree. This can usually be accomplished
with a high definition CT scan with reconstruc-
tion. If the tumor encroaches upon the hilus of
the liver, magnetic resonance cholangiopancrea-
tography (MRCP) may be of benefit in evaluat-
ing the hilus, especially the biliary tree.
Consideration should be given to using PET
scan to detect distant metastatic disease and
laparoscopy to detect metastatic disease in the
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abdomen, as well as to examine local involve-
ment with laparoscopic ultrasound. The exact
criteria for unresectability are listed in Figure 2.
The patients must be fit for resection. They
should not have metastatic disease. They should
not have bilateral or contralateral involvement
of the portal vein, hepatic artery, or secondary
biliary radicals. In some instances, however,
minimal bilateral portal vein involvement can
be cleared with resection, if far enough away
from the umbilical fissure. Additionally, there
should be a sufficient future liver remnant with at
least 30% of the liver volume of relatively normal
non-atrophied parenchyma that has good vascu-
lar inflow, outflow, and biliary drainage.
. For consideration of resectability for hilar cho-
langiocarcinoma (Figure 1), patients must be
medically fit for resection. They should be
subject to appropriate preoperative studies in-
cluding those focusing on hepatic function and
more directed studies in accordance with their
medical history. They should be studied for the
presence of metastatic disease in the peritoneal
cavity and thorax and elsewhere, if symptomatic.
Typically, a high definition CT scan of the chest,
abdomen, and pelvis is sufficient. Local involve-
ment of the main tumor mass should be studied
with particular attention to the portal vein,
hepatic artery, and hepatic parenchyma. This
can be accomplished with a high definition CT
scan with reconstructions. Biliary involvement
should be evaluated with either percutaneous
transhepatic cholangiogram (PTC) or MRCP.
Consideration should be given to using PET
scan to detect distant metastatic disease and
laparoscopy to detect metastatic disease in the
abdomen, as well as to examine local involve-
ment with laparoscopic ultrasound. The exact
criteria for unresectability are listed in Figure 2.
The patients must be fit for resection. They
Medically fit patient
History and physical exam
Laboratory/functional tests
No distant metastatic disease 
Peritoneal cavity and thorax         }CT*#
Other tests directed at symptoms
Peripheral – Local involvement 
Vascular Inflow
Vascular Outflow
Parencyma
Bile duct
Hilar – Local involvement
Portal vein
Hepatic artery     CT#
Parenchyma
Bile duct          } PTD or MRCP
Distal – Local involvement
Portal/superior mesenteric vein            
Superior mesenteric artery
Hepatic artery
Bile duct&
CT +/-
MRCP# CT
*Consider PET (peripheral and hair only) 
#Consider laparoscopy
&Consider ERCP, MRCP, or EUS if
no mass and to rule out stone
Figure 1. Cholangiocarcinoma  staging.
Medically unfit patient
Distant metastatic disease 
Nonsatellite hepatic metastases
Lymph node metastases beyond portal vein, 
hepatic artery, (celiac axis, and peripancreatic) 
distribution
Distant metastases in other organ/sites
Extensive Local involvement
Bilateral (or contralateral) involvement of
Portal vein (some rarely resectable)
Hepatic artery
Secondary biliary radicals
Inadequate future liver remnant
< 30% FLR in patient with normal (nonatrophied) 
hepatic parenchyma
< 2 contiguous segments with adequate portal 
venous and hepatic arterial inflow, adequate 
hepatic venous drainage, and adequate biliary
drainage
Medically unfit patient
Distant metastatic disease
Distant metastases (liver + other organs)
Lymph node metastases beyond portal vein, 
hepatic artery, peripancreatic, (and celiac 
axis) distribution
Major vascular involvement
Significant portal/SMV vein
Superior mesenteric artery
Common or proper hepatic artery
Peripheral or Hilar Distal
Figure 2. Cholangiocarcinoma  criteria of unresectability.
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should not have metastatic disease nor bilateral
or contralateral involvement of the portal vein,
hepatic artery, or secondary biliary radicals. In
some instances, however, minimal bilateral por-
tal vein involvement can be cleared with resection
if far enough away from the umbilical fissure.
Additionally, there should be a sufficient future
liver remnant with at least 30% of the liver
volume of relatively normal non-atrophied par-
enchyma that has good vascular inflow, outflow,
and biliary drainage.
. For consideration of resectability for distal cho-
langiocarcinoma (Figure 1), as before (Figure 1),
patients are reviewed to make sure that they are
medically fit, and that they do not have metastatic
disease. Local involvement generally focuses
on the portal/superior mesenteric vein complex,
superior mesenteric artery, and hepatic artery.
All this can usually be completed with a high
definition CT scan with reconstructions. Some-
times endoscopic retrograde pancreatography
(ERCP), MRCP, or endoscopic ultrasound can
help delineate the disease process if no mass is
seen on CT scan, or if a biliary stone is of concern.
Patients are unresectable if they are medically
unfit, if they have metastatic disease, or if they
have significant vascular involvement. If the
hepatic artery, or superior mesenteric, is signifi-
cantly involved (180 degree involvement), or if
the portal or superior mesenteric vein is signifi-
cantly involved (2 cm requiring resection), then
the patient is considered unresectable.
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